^
Association details:
| Biomarker: | MLL-MLLT1 fusion |
|---|---|
| Cancer: | B Acute Lymphoblastic Leukemia |
| Drug: | dactolisib (RTB101) (mTOR inhibitor, PI3K inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia
Published date:
09/29/2020
Excerpt:
...a female patient first diagnosed with a pro-B ALL carrying the t(11;19) translocation and molecular analysis showing a KMT2A/MLLT1 fusion transcript…Assessment of MRD by RT-PCR for KMT2A/MLLT1 transcripts and immunoglobulin gene rearrangement analysis demonstrated complete molecular response 6 years after starting BEZ235...
DOI:
10.1186/s40360-020-00446-x
Trial ID:
